Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06922604 · ClinicalTrials.gov registry record · Phase 1

Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma

A Phase 1 study of Primary Central Nervous System Lymphoma and Secondary Central Nervous System Lymphoma, sponsored by City of Hope Medical Center.

Recruiting
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT06922604 is a Phase 1 study of Primary Central Nervous System Lymphoma and Secondary Central Nervous System Lymphoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 20 participants, below the 51-participant average among 12 other Primary Central Nervous System Lymphoma trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06922604, a Phase 1 study of Primary Central Nervous System Lymphoma and Secondary Central Nervous System Lymphoma, is actively recruiting participants, sponsored by City of Hope Medical Center.

RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This phase Ib trial tests the safety and side effects of glofitamab after pre-treatment with obinutuzumab and how well they work in treating patients with central nervous system (CNS) lymphoma. Glofitamab is a bispecific antibody that can bind to two different antigens (substances that cause the body to make a specific immune response) at the same time. Glofitamab binds to CD20 on lymphoma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Obinutuzumab can also be administered as a pre-treatment to make glofitamab safer and more tolerable. Giving glofitamab with obinutuzumab pre-treatment may be safe, tolerable, and/or effective in treating patients with CNS lymphoma.

Conditions Studied

Primary Central Nervous System Lymphoma Secondary Central Nervous System Lymphoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Lumbar Puncture
  • PROCEDURE Magnetic Resonance Imaging
  • BIOLOGICAL Glofitamab

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-07-30
Est. Completion 2029-01-02
Phase Phase 1

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06922604

The ClinicalTrials.gov registry entry for NCT06922604 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 51-participant average among 12 other Primary Central Nervous System Lymphoma trials with a reported enrollment target (61% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Primary Central Nervous System Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06922604 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06922604 about?

NCT06922604 is a clinical study titled "Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma". This phase Ib trial tests the safety and side effects of glofitamab after pre-treatment with obinutuzumab and how well they work in treating patients with central nervous system (CNS) lymphoma. Glofitamab is a bispecific antibody that can bind to two different antigens (substances that cause the bod...

What is the current status of trial NCT06922604?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-07-30. Estimated completion is 2029-01-02.

What conditions does trial NCT06922604 study?

This clinical trial studies the following conditions: Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma.

What interventions are being tested in trial NCT06922604?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Lumbar Puncture (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Glofitamab (BIOLOGICAL).

Who is sponsoring clinical trial NCT06922604?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06922604 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Primary Central Nervous System Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Primary Central Nervous System Lymphoma

All registered trials for this condition

Secondary Central Nervous System Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.